Use of tilmicosin for treatment of pasteurellosis in rabbits

Sharon G. McKay From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by Sharon G. McKay in
Current site
Google Scholar
PubMed
Close
,
Douglas W. Morck From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by Douglas W. Morck in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
John K. Merrill From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by John K. Merrill in
Current site
Google Scholar
PubMed
Close
 PhD
,
Merle E. Olson From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by Merle E. Olson in
Current site
Google Scholar
PubMed
Close
 MSc, DVM
,
Siu C. Chan From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by Siu C. Chan in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Kathleen M. Pap From the Departments of Biological Sciences (McKay, Morck) and Microbiology and Infectious Diseases (Olson), The University of Calgary, 2500 University Dr NW, Calgary, Alberta, Canada T2N 1N4; Elanco, Division of Eli Lilly Canada Inc, Calgary, Alberta, Canada T2H 2L8 (Merrill); and Foothills Hospital, Calgary, Alberta, Canada T2N 2T9 (Chan, Pap).

Search for other papers by Kathleen M. Pap in
Current site
Google Scholar
PubMed
Close

Click on author name to view affiliation information

Abstract

Objectives

To determine tilmicosin concentrations in serum and tissues of rabbits given a single dose of 25 mg of tilmicosin/kg of body weight. To examine the effects of tilmicosin treatment (25 mg/kg, SC) in rabbits with pasteurellosis.

Procedure

After receipt of tilmicosin, healthy New Zealand White female rabbits (n = 3 at each time) were euthanatized at 2, 4, 8, 24, 48, and 72 hours for collection of blood samples and tissue specimens; 4 rabbits served as untreated controls. Rabbits (male and female) with pasteurellosis (n = 42) also were treated. Tilmicosin concentration was determined in serum, lung, and uterine tissues. Rabbits with pasteurellosis were treated with tilmicosin. Response was monitored, using bacteriologic culturing and antibiotic resistance and susceptibility testing, and by scoring clinical signs of disease.

Results

Serum tilmicosin concentration reached 1.91 ±0.18 μg/ml after 2 hours, decreased to 0.77 ± 0.07 μg/ml by 8 hours, and was below minimum inhibitory concentrations for Pasteurella multocida at 24 hours. Terminal half-life in serum was 5.97 hours. Lung and uterus concentrations were 14.43 ± 1.34 and 11.57 ± 0.09 ppm at 2 hours, and were 5.10 ± 1.05 and 8.87 ± 1.66 ppm at 24 hours, respectively. 69% (29/42) of rabbits with pasteurellosis responded favorably in 3 days. Second treatment was required in 31% (13/42), and 5 of these rabbits had clinical signs on day 6; 2 of these 5 had improved. Treatment success rate was 93% (39/42). Of the rabbits that were culture positive on day 0, 35% (6/17) remained positive on day 3. 1 of 6 rabbits was culture positive on day 6.

Conclusion

Tilmicosin (25 mg/kg, SC) was an effective treatment for pasteurellosis in New Zealand White rabbits.

Clinical Relevance

Tilmicosin treatment of pasteurellosis in rabbits is useful in research rabbits and in those destined for meat production. A single dose of antibiotic minimizes stress-associated handling. (Am J Vet Res 1996;57:1180-1184)

Abstract

Objectives

To determine tilmicosin concentrations in serum and tissues of rabbits given a single dose of 25 mg of tilmicosin/kg of body weight. To examine the effects of tilmicosin treatment (25 mg/kg, SC) in rabbits with pasteurellosis.

Procedure

After receipt of tilmicosin, healthy New Zealand White female rabbits (n = 3 at each time) were euthanatized at 2, 4, 8, 24, 48, and 72 hours for collection of blood samples and tissue specimens; 4 rabbits served as untreated controls. Rabbits (male and female) with pasteurellosis (n = 42) also were treated. Tilmicosin concentration was determined in serum, lung, and uterine tissues. Rabbits with pasteurellosis were treated with tilmicosin. Response was monitored, using bacteriologic culturing and antibiotic resistance and susceptibility testing, and by scoring clinical signs of disease.

Results

Serum tilmicosin concentration reached 1.91 ±0.18 μg/ml after 2 hours, decreased to 0.77 ± 0.07 μg/ml by 8 hours, and was below minimum inhibitory concentrations for Pasteurella multocida at 24 hours. Terminal half-life in serum was 5.97 hours. Lung and uterus concentrations were 14.43 ± 1.34 and 11.57 ± 0.09 ppm at 2 hours, and were 5.10 ± 1.05 and 8.87 ± 1.66 ppm at 24 hours, respectively. 69% (29/42) of rabbits with pasteurellosis responded favorably in 3 days. Second treatment was required in 31% (13/42), and 5 of these rabbits had clinical signs on day 6; 2 of these 5 had improved. Treatment success rate was 93% (39/42). Of the rabbits that were culture positive on day 0, 35% (6/17) remained positive on day 3. 1 of 6 rabbits was culture positive on day 6.

Conclusion

Tilmicosin (25 mg/kg, SC) was an effective treatment for pasteurellosis in New Zealand White rabbits.

Clinical Relevance

Tilmicosin treatment of pasteurellosis in rabbits is useful in research rabbits and in those destined for meat production. A single dose of antibiotic minimizes stress-associated handling. (Am J Vet Res 1996;57:1180-1184)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 97 97 23
PDF Downloads 41 41 5
Advertisement